2seventy bio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
27 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Abecma (idecabtagene vicleucel) / BMS
KarMMa-9, NCT06399393: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Recruiting
3
618
Europe, Canada, Japan, US, RoW
idecabtagene vicleucel, BMS-986395, Abecma, bb2121, ide-cel, Lenalidomide, Revlimid, LEN, Fludarabine, FLUDARA, BENDARBIN, Cyclophosphamide, ENDOXAN, CYTOXAN
Celgene, Bristol-Myers Squibb
Multiple Myeloma
03/31
07/32
KarMMa-3, NCT03651128 / 2018-001023-38: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Oct 2022 - Dec 2023: Approval in US for 3-5L multiple myeloma
Hourglass Jun 2023 - Jun 2023 : Subgroup analysis of outcomes for patients with high-risk r/r multiple myeloma from the KarMMa-3 trial at EHA 2023
Checkmark Data from KarMMa-3 trial for 3L multiple myeloma
Aug 2022 - Aug 2022: Data from KarMMa-3 trial for 3L multiple myeloma
Active, not recruiting
3
381
Europe, Canada, Japan, US
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Celgene
Multiple Myeloma
04/27
04/27
KarMMa-9, NCT06045806: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Active, not recruiting
3
618
Europe, Canada, Japan, US, RoW
idecabtagene vicleucel, BMS-986395, Abecma, bb2121, ide-cel, Lenalidomide, Revlimid, LEN, Fludarabine, FLUDARA, BENDARBIN, Cyclophosphamide, ENDOXAN, CYTOXAN
Celgene, Bristol-Myers Squibb, 2seventy bio
Multiple Myeloma
08/25
08/25
KarMMa-2, NCT03601078 / 2018-000264-28: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Hourglass Jun 2023 - Jun 2023 : Data from KarMMa-2 trial for 2L multiple myeloma at EHA 2023
Checkmark Presentation of data from KarMMa-2 trial for Multiple Myeloma at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from KarMMa-2 trial for Multiple Myeloma at ASH 2022
Checkmark Data from KarMMa-2 trial for 2L multiple myeloma at ASH 2022
Nov 2022 - Nov 2022: Data from KarMMa-2 trial for 2L multiple myeloma at ASH 2022
More
Active, not recruiting
2
264
Europe, US
bb2121, BMS-986395, Lenalomide, Revlimid®, Talquetamab, TALVEY
Celgene
Multiple Myeloma
10/25
10/25
NCT06138275: Elranatamab in R/R Multiple Myeloma

Recruiting
2
32
US
Elranatamab
Massachusetts General Hospital, Pfizer
Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
12/25
12/28
BMTCTN1902, NCT05032820: MM CAR-T to Upgrade Response

Completed
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
08/24
02/25
NCT06179888: Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Recruiting
2
78
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Iberdomide, CC 220, CC-220, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Patient Monitoring, medical monitoring, monitor, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Skeletal Survey X-Ray, Skeletal Survey
National Cancer Institute (NCI)
Multiple Myeloma
10/27
10/27
KarMMa, NCT03361748 / 2017-002245-29: Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Checkmark Approved in Japan for the 4L treatment of adult patients with R/R multiple myeloma
Jan 2022 - Jan 2022: Approved in Japan for the 4L treatment of adult patients with R/R multiple myeloma
Checkmark Data from KarMMa trial for r/r multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: Data from KarMMa trial for r/r multiple myeloma at ASH 2021
Checkmark Approved in EU for relapsed and refractory 4L multiple myeloma based on KarMMa study
More
Completed
2
149
Europe, Canada, Japan, US
bb2121
Celgene
Multiple Myeloma
12/23
12/23
NCT06523621: Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Recruiting
2
50
US
Nivolumab, Opdivo
Wake Forest University Health Sciences, Atrium Health Levine Cancer Institute, Bristol-Myers Squibb
Multiple Myeloma
11/27
11/27
NCT05393804: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

Recruiting
2
32
US
Ide-cel (bb2121)
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
05/26
05/26
NCT03642626: MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, not recruiting
2
144
US
KYMRIAH, tisagenlecleucel, YESCARTA, Fludarabine 30mg/m2 4 doses, Cyclophosphamide 500 mg/m2; 2 doses, Fludarabine 30mg/m2 3 doses, Cyclophosphamide 500 mg/m2; 3 doses, Fludarabine 25mg/m2 3 days, Cyclophosphamide 250 mg/m2; 3 days, Tecartus, Brexucabtagene Autoleucel, Abecma, Intravenous Suspension, Cyclophosphamide 900 mg/m2; 1 day, Breyanzi Injectable Product
Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
02/24
06/28
NCT06518551: Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Recruiting
1/2
49
US
Elotuzumab, BMS-901608, Iberdomide, CC-220, Iberdomide hydrochloride, C25H28N3O5Cl, BMS-986382, Dexamethasone, Decadron, 9- fluoro11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione
Omar Nadeem, MD, Celgene, Bristol-Myers Squibb
Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
12/29
12/34
KarMMa-7, NCT04855136 / 2020-003248-10: Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Completed
1/2
21
Europe, US
BB2121, ide-cel, CC-220, BMS-986405, JSMD194
Celgene
Multiple Myeloma
04/25
04/25
KarMMa-4, NCT04196491: A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Completed
1
13
US
bb2121, ide-cel, Fludarabine, Cyclophosphamide, Lenalidomide
Celgene
Multiple Myeloma
06/23
06/23
NCT06048250: Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

Recruiting
1
15
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Mezigdomide, BMS 986348, BMS-986348, BMS986348, CC 92480, CC-92480, CELMoD CC-92480, Cereblon E3 Ligase Modulation Drug CC-92480, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480, Cereblon Modulator CC-92480, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Multiple Myeloma
03/26
03/26
ABE-DESCART, NCT06154902: Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

Active, not recruiting
N/A
350
Europe
Idecabtagene vicleucel, Not treated
Bristol-Myers Squibb
Multiple Myeloma
07/27
12/27
NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Available
N/A
NA
Nonconforming idecabtagene vicleucel, BB2121
Celgene
Multiple Myeloma
 
 
NCT06357754: Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Recruiting
N/A
50
Europe, Japan, US
Idecabtagene vicleucel, Lisocabtagene maraleucel
Bristol-Myers Squibb
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
10/38
10/38
CA089-1081, NCT06698887: A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

Recruiting
N/A
15
RoW
Idecabtagene vicleucel
Bristol-Myers Squibb
Multiple Myeloma
03/31
03/31
NIMMS, NCT06855121: The Norwegian Immunotherapy in Multiple Myeloma Study

Recruiting
N/A
400
Europe
Teclistamab, Elranatamab, Ciltacabtagene Autoleucel, Talquetamab, Idecabtagene vicleucel
St. Olavs Hospital, Norwegian University of Science and Technology, Haukeland University Hospital, Stavanger University Hospital, Norway, Oslo University Hospital, University Hospital, Akershus, Sykehuset i Vestfold Hospital Trust, University Hospital of North Norway, Ålesund Hospital, Norway, Helse Nord-Trøndelag HF, Sorlandet Hospital HF, Førde Hospital Trust, Molde Hospital, Bodø Hospital, Norway, Helse Fonna, Volda Hospital, Diakonhjemmet Hospital, Telemark Hospital Trust, Kristiansund Hospital, Vestre Viken Hospital Trust, Lovisenberg Diakonale Hospital, Sykehuset Innlandet HF
Myeloma Multiple, Plasma Cell Leukemia, AL Amyloidosis
01/29
12/37
bb21217 / BMS, Regeneron
CRB-402, NCT03274219: Study of bb21217 in Multiple Myeloma

Hourglass Dec 2021 - Dec 2021 : From CRB-402 trial for multiple myeloma at ASH 2021
Checkmark Data from trial for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from trial for multiple myeloma at ASH 2020
Checkmark Data from KarMMa trial for r/r multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: Data from KarMMa trial for r/r multiple myeloma at ASH 2019
More
Completed
1
72
US
bb21217
2seventy bio
Multiple Myeloma
12/22
12/22
T-cell receptor therapy / Regeneron
NCT04614571: T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge

Completed
N/A
24
US
Gluten Powder
Regeneron Pharmaceuticals
Celiac Disease
05/24
05/24
JWTCR001 / Medigene, Regeneron
NCT06170294: MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Recruiting
1
20
RoW
TCR-MAGE-A4 T-Cells, MAGE-A4-directed T cell receptor-engineered T Cells
Peking University, Shanghai Ming Ju Biotechnology Co., Ltd.
Advanced Solid Tumor
12/25
12/28
MCC1 TCR / Fred Hutchinson Cancer Center, Affini-T Therap, Regeneron
ATTAC-MCC, NCT03747484: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Terminated
1/2
7
US
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1, FH-MCVA2TCR, FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1, Avelumab, 1537032-82-8, Bavencio, Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody, MSB-0010718C, MSB0010718C, Pembrolizumab, Anti-(Human Programmed Cell Death 1), Keytruda, Lambrolizumab, MK-3475, SCH 900475, Interferon Gamma-1b, 98059-61-1, Actimmune, gamma Interferon 1B, IFN-g-1b, IFN-gamma 1b, Recombinant Interferon Gamma-1b
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), Affini-T Therapeutics, Inc.
Other Skin
01/24
01/24
DARIC33 / Regeneron
PLAT-08, NCT05105152: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Recruiting
1
18
US
SC-DARIC33
Seattle Children's Hospital, 2seventy bio
Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
02/26
01/41
bbT369 / Regeneron
CRC-403, NCT05169489: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Active, not recruiting
1/2
15
US
bbT369
Regeneron Pharmaceuticals
Diffuse Large B Cell Lymphoma (DLBCL)
08/25
08/25
27T51 / Regeneron
NCT06469281: A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Recruiting
1
90
US
27T51, Cemiplimab, Libtayo, REGN2810, Bevacizumab, Avastin, Mvasi, Vegzelma, Zirabe
Regeneron Pharmaceuticals
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
07/28
06/29
Multi-targeted CAR-T cells / Regeneron
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Abecma (idecabtagene vicleucel) / BMS
KarMMa-9, NCT06399393: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Recruiting
3
618
Europe, Canada, Japan, US, RoW
idecabtagene vicleucel, BMS-986395, Abecma, bb2121, ide-cel, Lenalidomide, Revlimid, LEN, Fludarabine, FLUDARA, BENDARBIN, Cyclophosphamide, ENDOXAN, CYTOXAN
Celgene, Bristol-Myers Squibb
Multiple Myeloma
03/31
07/32
KarMMa-3, NCT03651128 / 2018-001023-38: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Oct 2022 - Dec 2023: Approval in US for 3-5L multiple myeloma
Hourglass Jun 2023 - Jun 2023 : Subgroup analysis of outcomes for patients with high-risk r/r multiple myeloma from the KarMMa-3 trial at EHA 2023
Checkmark Data from KarMMa-3 trial for 3L multiple myeloma
Aug 2022 - Aug 2022: Data from KarMMa-3 trial for 3L multiple myeloma
Active, not recruiting
3
381
Europe, Canada, Japan, US
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Celgene
Multiple Myeloma
04/27
04/27
KarMMa-9, NCT06045806: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Active, not recruiting
3
618
Europe, Canada, Japan, US, RoW
idecabtagene vicleucel, BMS-986395, Abecma, bb2121, ide-cel, Lenalidomide, Revlimid, LEN, Fludarabine, FLUDARA, BENDARBIN, Cyclophosphamide, ENDOXAN, CYTOXAN
Celgene, Bristol-Myers Squibb, 2seventy bio
Multiple Myeloma
08/25
08/25
KarMMa-2, NCT03601078 / 2018-000264-28: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Hourglass Jun 2023 - Jun 2023 : Data from KarMMa-2 trial for 2L multiple myeloma at EHA 2023
Checkmark Presentation of data from KarMMa-2 trial for Multiple Myeloma at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from KarMMa-2 trial for Multiple Myeloma at ASH 2022
Checkmark Data from KarMMa-2 trial for 2L multiple myeloma at ASH 2022
Nov 2022 - Nov 2022: Data from KarMMa-2 trial for 2L multiple myeloma at ASH 2022
More
Active, not recruiting
2
264
Europe, US
bb2121, BMS-986395, Lenalomide, Revlimid®, Talquetamab, TALVEY
Celgene
Multiple Myeloma
10/25
10/25
NCT06138275: Elranatamab in R/R Multiple Myeloma

Recruiting
2
32
US
Elranatamab
Massachusetts General Hospital, Pfizer
Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
12/25
12/28
BMTCTN1902, NCT05032820: MM CAR-T to Upgrade Response

Completed
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
08/24
02/25
NCT06179888: Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Recruiting
2
78
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Iberdomide, CC 220, CC-220, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Patient Monitoring, medical monitoring, monitor, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Skeletal Survey X-Ray, Skeletal Survey
National Cancer Institute (NCI)
Multiple Myeloma
10/27
10/27
KarMMa, NCT03361748 / 2017-002245-29: Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Checkmark Approved in Japan for the 4L treatment of adult patients with R/R multiple myeloma
Jan 2022 - Jan 2022: Approved in Japan for the 4L treatment of adult patients with R/R multiple myeloma
Checkmark Data from KarMMa trial for r/r multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: Data from KarMMa trial for r/r multiple myeloma at ASH 2021
Checkmark Approved in EU for relapsed and refractory 4L multiple myeloma based on KarMMa study
More
Completed
2
149
Europe, Canada, Japan, US
bb2121
Celgene
Multiple Myeloma
12/23
12/23
NCT06523621: Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Recruiting
2
50
US
Nivolumab, Opdivo
Wake Forest University Health Sciences, Atrium Health Levine Cancer Institute, Bristol-Myers Squibb
Multiple Myeloma
11/27
11/27
NCT05393804: A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

Recruiting
2
32
US
Ide-cel (bb2121)
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
05/26
05/26
NCT03642626: MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, not recruiting
2
144
US
KYMRIAH, tisagenlecleucel, YESCARTA, Fludarabine 30mg/m2 4 doses, Cyclophosphamide 500 mg/m2; 2 doses, Fludarabine 30mg/m2 3 doses, Cyclophosphamide 500 mg/m2; 3 doses, Fludarabine 25mg/m2 3 days, Cyclophosphamide 250 mg/m2; 3 days, Tecartus, Brexucabtagene Autoleucel, Abecma, Intravenous Suspension, Cyclophosphamide 900 mg/m2; 1 day, Breyanzi Injectable Product
Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
02/24
06/28
NCT06518551: Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Recruiting
1/2
49
US
Elotuzumab, BMS-901608, Iberdomide, CC-220, Iberdomide hydrochloride, C25H28N3O5Cl, BMS-986382, Dexamethasone, Decadron, 9- fluoro11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione
Omar Nadeem, MD, Celgene, Bristol-Myers Squibb
Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
12/29
12/34
KarMMa-7, NCT04855136 / 2020-003248-10: Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Completed
1/2
21
Europe, US
BB2121, ide-cel, CC-220, BMS-986405, JSMD194
Celgene
Multiple Myeloma
04/25
04/25
KarMMa-4, NCT04196491: A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Completed
1
13
US
bb2121, ide-cel, Fludarabine, Cyclophosphamide, Lenalidomide
Celgene
Multiple Myeloma
06/23
06/23
NCT06048250: Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

Recruiting
1
15
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Mezigdomide, BMS 986348, BMS-986348, BMS986348, CC 92480, CC-92480, CELMoD CC-92480, Cereblon E3 Ligase Modulation Drug CC-92480, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480, Cereblon Modulator CC-92480, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Multiple Myeloma
03/26
03/26
ABE-DESCART, NCT06154902: Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

Active, not recruiting
N/A
350
Europe
Idecabtagene vicleucel, Not treated
Bristol-Myers Squibb
Multiple Myeloma
07/27
12/27
NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Available
N/A
NA
Nonconforming idecabtagene vicleucel, BB2121
Celgene
Multiple Myeloma
 
 
NCT06357754: Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Recruiting
N/A
50
Europe, Japan, US
Idecabtagene vicleucel, Lisocabtagene maraleucel
Bristol-Myers Squibb
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
10/38
10/38
CA089-1081, NCT06698887: A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea

Recruiting
N/A
15
RoW
Idecabtagene vicleucel
Bristol-Myers Squibb
Multiple Myeloma
03/31
03/31
NIMMS, NCT06855121: The Norwegian Immunotherapy in Multiple Myeloma Study

Recruiting
N/A
400
Europe
Teclistamab, Elranatamab, Ciltacabtagene Autoleucel, Talquetamab, Idecabtagene vicleucel
St. Olavs Hospital, Norwegian University of Science and Technology, Haukeland University Hospital, Stavanger University Hospital, Norway, Oslo University Hospital, University Hospital, Akershus, Sykehuset i Vestfold Hospital Trust, University Hospital of North Norway, Ålesund Hospital, Norway, Helse Nord-Trøndelag HF, Sorlandet Hospital HF, Førde Hospital Trust, Molde Hospital, Bodø Hospital, Norway, Helse Fonna, Volda Hospital, Diakonhjemmet Hospital, Telemark Hospital Trust, Kristiansund Hospital, Vestre Viken Hospital Trust, Lovisenberg Diakonale Hospital, Sykehuset Innlandet HF
Myeloma Multiple, Plasma Cell Leukemia, AL Amyloidosis
01/29
12/37
bb21217 / BMS, Regeneron
CRB-402, NCT03274219: Study of bb21217 in Multiple Myeloma

Hourglass Dec 2021 - Dec 2021 : From CRB-402 trial for multiple myeloma at ASH 2021
Checkmark Data from trial for multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from trial for multiple myeloma at ASH 2020
Checkmark Data from KarMMa trial for r/r multiple myeloma at ASH 2019
Dec 2019 - Dec 2019: Data from KarMMa trial for r/r multiple myeloma at ASH 2019
More
Completed
1
72
US
bb21217
2seventy bio
Multiple Myeloma
12/22
12/22
T-cell receptor therapy / Regeneron
NCT04614571: T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge

Completed
N/A
24
US
Gluten Powder
Regeneron Pharmaceuticals
Celiac Disease
05/24
05/24
JWTCR001 / Medigene, Regeneron
NCT06170294: MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Recruiting
1
20
RoW
TCR-MAGE-A4 T-Cells, MAGE-A4-directed T cell receptor-engineered T Cells
Peking University, Shanghai Ming Ju Biotechnology Co., Ltd.
Advanced Solid Tumor
12/25
12/28
MCC1 TCR / Fred Hutchinson Cancer Center, Affini-T Therap, Regeneron
ATTAC-MCC, NCT03747484: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Terminated
1/2
7
US
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1, FH-MCVA2TCR, FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1, Avelumab, 1537032-82-8, Bavencio, Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody, MSB-0010718C, MSB0010718C, Pembrolizumab, Anti-(Human Programmed Cell Death 1), Keytruda, Lambrolizumab, MK-3475, SCH 900475, Interferon Gamma-1b, 98059-61-1, Actimmune, gamma Interferon 1B, IFN-g-1b, IFN-gamma 1b, Recombinant Interferon Gamma-1b
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), Affini-T Therapeutics, Inc.
Other Skin
01/24
01/24
DARIC33 / Regeneron
PLAT-08, NCT05105152: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Recruiting
1
18
US
SC-DARIC33
Seattle Children's Hospital, 2seventy bio
Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
02/26
01/41
bbT369 / Regeneron
CRC-403, NCT05169489: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Active, not recruiting
1/2
15
US
bbT369
Regeneron Pharmaceuticals
Diffuse Large B Cell Lymphoma (DLBCL)
08/25
08/25
27T51 / Regeneron
NCT06469281: A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Recruiting
1
90
US
27T51, Cemiplimab, Libtayo, REGN2810, Bevacizumab, Avastin, Mvasi, Vegzelma, Zirabe
Regeneron Pharmaceuticals
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
07/28
06/29
Multi-targeted CAR-T cells / Regeneron
No trials found

Download Options